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Errata
In the December 2000 issue of the Journal (115:6, 1021±1028) an author was
missing from the paper ``Expression of Proopiomelanocortin Peptides in Human
Dermal Microvascular Endothelial Cells: Evidence for a Regulation by
Ultraviolet Light and Interleukin-1''. The correct author list is as follows:
Thomas E. Scholzen, Dirk-Henner Kalden, Thomas Brzoska, Tanja Fisbeck, Michaela
Fastrich, Meinhard Schiller, Markus BoÈhm, T. Schwarz, Cheryl A. Armstrong, John C.
Ansel, and Thomas A. Luger
The authors apologize for any inconvenience caused.
In the January 2001 issue of the Journal (116:1, 118±123) a number of author corrections
were not included in the ®nal published version of the paper ``Isoform-Selective
Upregulation of Mast Cell Chymase in the Development of Skin Fibrosis in Scleroderma
Model Mice''. These corrections are as follows:
page 118, right column, line 7, ``its granular ultrastructure'' should be ``the ultrastructure
of its secretory granules''.
page 119, right column, line 30, ``in 20 ml of Tris-HCl'' should be ``in 20 ml of 50 mM
Tris-HCl''.
page 119, right column, line 37, ``10 mM Tris-HCl'' should be ``10 mM Tris-HCl''.
page 119, right column, line 44, ``antisense primer 5¢-GAA GAC TCT GAT GCA CGC
AGG TC-3¢'' should be ``antisense primer 5¢-GAA GAC TCT GAT TGC ACG CAG
GTC-3¢''.
page 119, right column, line 55, ``654 and 490 bp'' ahould be ``655 and 491 bp''.
page 119, right column, line 4 up, ``factors of 1.33 (654 bp/490 bp)'' ahould be ``factors of
1.33 (655 bp/491 bp)''.
page 123, left column, line 39, ``Fukamizu'' should be ``Fukami''.
page 123, footnote 1, ``Fukamizu'' should be ``Fukami''.
In the February 2001 issue of the Journal (116:2, 319±329) Table II was printed
incorrectly in the paper ``Response of Psoriasis to Interleukin-10 is Associated with
Suppression of Cutaneous Type 1 In¯ammation, Downregulation of the Epidermal
Interleukin-8/CXCR2 Pathway and Normalization of Keratinocyte Maturation''. The
correct table is as follows:
Table II. Carriage of TNFa promoter polymorphisms and clinical response to
IL-10 therapya
TNFa-238 TNFa-308
Moderate n = 4 G/G G/G n = 0
response G/A G/G n = 2
G/G G/A n = 2
Marked n = 10 G/G G/G n = 5
response G/A G/G n = 2
G/G G/A n = 3
aGenotypic analysis of polymorphisms at positions ±238 and ±308 of the TNFa promoter in patients treated
with IL-10. Allelic variations were investigated by PCR/RFLP (TNF-238.2 allele: A at ±238) or allele-
speci®c PCR (TNF-308.2 allele: A at ±308). Individuals homozygous for the wild-type allele (G at both
positions) were detected in half of patients with marked clinical response (PASI reduction > 50%). All patients
with moderate clinical response (PASI reduction < 50%, > 25%) were carriers of variant alleles.
